What is the ticker symbol for Travere Therapeutics?

Travere Therapeutics trades under the ticker TVTX on NASDAQ.

What sector does Travere Therapeutics operate in?

Travere Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze TVTX in a portfolio?

PortView shows TVTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Travere Therapeutics (TVTX) Stock Analysis

NASDAQHealthcareBiotechnology

$66.56+1.29%

1-year price historyRange $19.61 – $67.52

52-week range$66.56

$18.13$67.85

What Travere Therapeutics does

Travere Therapeutics, Inc. is a biopharmaceutical company developing therapies for rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral, once-daily, non-immunosuppressive medication targeting two pathways of disease progression (endothelin-1 and angiotensin-II). Sparsentan received accelerated FDA approval in February 2023 and full approval in September 2024 to slow kidney function decline in adults with primary IgA nephropathy (IgAN) at risk of progression. In April 2026, the FDA approved FILSPARI to reduce proteinuria in adult and pediatric patients aged 8 and older with focal segmental glomerulosclerosis (FSGS) without nephrotic syndrome, making it the first and only FDA-approved medicine for FSGS. The company also markets Thiola and Thiola EC (tiopronin tablets) for cystinuria, a rare genetic disorder causing recurring kidney stones. Its pipeline includes pegtibatinase, an investigational enzyme replacement therapy for classical homocystinuria (HCU). Formerly Retrophin, Inc. (renamed November 2020), Travere is headquartered in San Diego, California, and incorporated in Delaware.

Key metrics

Market cap

$6.19B

P/E (TTM)

-147.91

EPS (TTM)

$-0.45

Beta

1.04

Dividend yield

0.00%

Revenue / share

$6.33

50-day avg

$59.74

200-day avg

$41.94

52-week high

$67.85

52-week low

$18.13

CEO

Eric Dube

ETFs linked to TVTX

Broad-market and Healthcare sector ETFs an investor holding Travere Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how TVTX fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze TVTX in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Travere Therapeutics?: Travere Therapeutics trades under the ticker TVTX on NASDAQ.
Which exchange is TVTX listed on?: TVTX is listed on NASDAQ.
What sector does Travere Therapeutics operate in?: Travere Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze TVTX in a portfolio?: PortView shows TVTX's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.